TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.

A cohort study finds the risk for acne in patients on JAK inhibitors for atopic dermatitis was about 2.5 times greater than ...

Rocatinlimab, targeting the OX40 pathway, shows significant efficacy in moderate to severe atopic dermatitis, marking a new therapeutic class in disease management. Long-term melanoma data reveal ...

Amlitelimab is an investigational anti-OX40 ligand monoclonal antibody designed to normalize the overactive immune response in patients with atopic dermatitis.

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 23 scientific posters at Maui Derm Hawaii 2026 (Jan. 25-29), showcasing a comprehensive body of evidence across ...

The two-time U.S. Olympic gold medalist gymnast opens up about her skin condition, her fashion dos and don’ts for eczema, and ...

Apogee Therapeutics (APGE) leverages IL-13 pathway optimization to enable less frequent dosing, targeting a leadership shift ...

For Tracy Owen, eczema was much more than dry skin. It came to dictate every aspect of her life, from ­relationships to how she dressed.

Welcome, everyone, to the JPMorgan Healthcare Conference. We are pleased to have with us the Almirall management team here with us today, Carlos Gallardo, Chairman and CEO; Karl Ziegelbauer, CFO; Jon ...

Background: The association between atopic dermatitis (AD) and lymphoma risk remains inconclusive. Dupilumab, approved for moderate-to-severe AD, has been linked to an increased lymphoma risk, raising ...

Once-daily oral ICP-332 results in large reduction in eczema scores and shows favorable safety in adults with moderate-to-severe atopic dermatitis.

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Hi, I'm Dr. Peter Lio. I'm a clinical ...